The company surged Monday on the news of Merck's (MRK) - Get Report acquisition of Idenix Pharmaceuticals (IDIX) . The stock continued to surge Tuesday after the FDA removed its clinical hold on sovaprevir, one of Achillion's four experimental hepatitis C treatments. The FDA had placed the hold in June because of abnormal liver results in patients. Achillion can now begin trials with a once-daily maximum dose of 200 mg of sovaprevir in hepatitis C patients and other healthy volunteers.
The stock was down 9.1% to $7.08 at 10:15 a.m.
Must Read: Warren Buffett's 25 Favorite Stocks
ACHN Price data by YCharts
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.